All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Bookmark this article
During the European Society of Hematology (ESH) 2nd How I manage: CAR T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma Hub spoke to André Baruchel, Hôpital Robert-Debré, Paris, FR. We asked, What is new in chimeric antigen receptor (CAR) T-cell therapy for pediatric acute lymphoblastic leukemia.
What is new in CAR T-cell therapy for pediatric acute lymphoblastic leukemia?
Baruchel discusses long-term results of clinical trials investigating CAR T-cell therapy and the benefits for pediatric patients with advanced acute lymphoblastic leukemia. He also mentions potential causes for relapse after CAR T-cell treatment and how new constructs could tackle this problem.
Your opinion matters
Phase I ZUMA-4 trial: Long-term follow-up of brexu-cel in pediatric/adolescent R/R B-ALL
During the EHA2021 Virtual Congress, the ALL Hub spoke with André Baruchel, Hôpital Robert-Debré, Paris, FR, about the long-term follow-up from the ZUMA-4...
Venetoclax and navitoclax for R/R ALL and lymphoblastic lymphoma
During the 2020 European Hematology Association (EHA) Annual Congress, our ALL Hub Steering Committee member, Elias Jabbour, presented results from a phase I trial (NCT03181126)...
Subscribe to get the best content related to ALL delivered to your inbox